Evidence map›Paper›PMID 38618977›Full record

ArticleFuture medicinal chemistry2024

Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.

Yong Yan, Hanwen Liu, Di Wu, Zhihao Gu, Wenhao Guo, Hequan Yao, Kejiang Lin, Xuanyi Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yong YanDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Hanwen LiuDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Di WuDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Zhihao GuDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Wenhao GuoDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Hequan YaoDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.ORCID 0000-0003-4865-820X
Kejiang LinDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.ORCID 0000-0001-6351-5683
Xuanyi LiDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.ORCID 0000-0003-4367-3005
China Pharmaceutical University · CN

Funding

National Natural Science Foundation of China 81903439
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus 3C ProteasesDrug DesignProtease InhibitorsSARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentHumansMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity Relationship3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors3CLpro3CLpro inhibitorsmolecular dockingSARS-CoV-2virtual screening based on pharmacophore

Identifiers

PMID38618977
PMCPMC11249163
OpenAlexW4394813627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.